EICHOR
● Active Not Recruiting
A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma
Condition: Hepatocellular Carcinoma · Sponsor: CStone Pharmaceuticals
About this study
This is a multi-center, double-blind, randomized, phase III study to investigate the efficacy and safety of Nofazinlimab (CS1003) in combination with lenvatinib and placebo in combination with lenvatinib in the treatment of subjects with no prior systemic treatment and with unresectable advanced hepatocellular carcinoma (HCC). Subjects cannot be eligible for locoregional therapy. In this study, Nofazinlimab (CS1003) (or placebo) and lenvatinib are both considered as the study treatment while Nofazinlimab (CS1003) (or placebo) is the investigational product and lenvatinib is selected as the basic treatment for HCC.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (74)
| Southern California Research Center | Coronado, California, United States | — |
| Inland Empire Liver Foundation | Rialto, California, United States | — |
| Mercy Medical Center | Baltimore, Maryland, United States | — |
| UMass Memorial Medical Center | Worcester, Massachusetts, United States | — |
| Stony Brook University Cancer Clinical Trials | Stony Brook, New York, United States | — |
| The First Affiliated Hospital of Bengbu Medical College | Bengbu, Anhui, China | — |
| The First Affiliated Hospital Of Anhui Medical University | Hefei, Anhui, China | — |
| The Second Affiliated Hospital of Anhui Medical University | Hefei, Anhui, China | — |
| Beijing Cancer Hospital | Beijing, Beijing Municipality, China | — |
| Beijing You'an Hospital, Capital Medical University | Beijing, Beijing Municipality, China | — |
| Peking Union Medical College Hospital | Beijing, Beijing Municipality, China | — |
| The 900th Hospital of Joint Logistic Support Force of PLA | Fuzhou, Fujian, China | — |
+ 62 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04194775